Accelera Competitors and Similar CompaniesClear all

Accelera's competitors and similar companies include Syneos Health, Parexel International, Medpace and Cell&Co Bioservices.

	Accelera Accelera is a contract research organization (CRO) specializing in preclinical research.	Syneos Health Syneos Health (formerly known as INC Research) is a biopharmaceutical solutions company.	Parexel International Parexel International (MA) is a clinical research organization.	Medpace Medpace is a clinical contract research organization (CRO).	Cell&Co Bioservices Cell and Co Bioservices (also known as Cryoport) is a company providing management solutions for biological and chemical samples.
Founding Date	Founding Date 2009	Founding Date 1998	Founding Date 1982	Founding Date 1992	Founding Date 2012
Type	Type Subsidiary	Type Subsidiary	Type Private	Type Public	Type Subsidiary
Tags	Tags Healthcare biotech clinical research pharma	Tags Healthcare biotech clinical research pharma	Tags Healthcare biotech clinical research pharma	Tags Healthcare biotech clinical research pharma	Tags Healthcare biotech clinical research pharma
Locations	Locations Nerviano, IT HQ	Locations Morrisville, US HQ Buenos Aires, AR Adelaide, AU Montréal, CA Québec, CA Toronto, CA Beijing, CN see more	Locations Newton, US HQ Olivos, AR Vicente López, AR Brisbane, AU Macquarie Park, AU Wavre, BE Sao Paulo, BR see more	Locations Cincinnati, US HQ Buenos Aires, AR South Yarra, AU Leuven, BE Leuven, BE Sao Paulo, BR Toronto, CA see more	Locations Clermont-Ferrand, FR HQ Pont Du Château, FR
Employees	Employees 63	Employees 29,000	Employees 20,806	Employees 5,90013% increase	Employees 343% increase
Financial
Revenue (est.)	Revenue (est.) €11.6m (Y, 2024)	Revenue (est.) $5.4b (FY, 2022)	Revenue (est.) N/A	Revenue (est.) $2.5b (FY, 2025)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods $4.1b (FY, 2022)	Cost of goods N/A	Cost of goods $1.8b (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit $1.3b (FY, 2022)	Gross profit N/A	Gross profit $760.6m (FY, 2025)	Gross profit N/A
Net income	Net income €4.3m (Y, 2024)	Net income $266.5m (FY, 2022)	Net income N/A	Net income $451.1m (FY, 2025)	Net income N/A
Operating ⚠
Backlog	Backlog N/A	Backlog $9.8b (Q1, 2023)	Backlog $4b (FY, 2017)	Backlog $2.7b (Q3, 2023)	Backlog N/A
Countries	Countries N/A	Countries 46 (FY, 2022)	Countries 52 (FY, 2017)	Countries 40 (Q3, 2023)	Countries N/A
Facilities	Facilities N/A	Facilities 96 (FY, 2022)	Facilities 8 (FY, 2017)	Facilities N/A	Facilities N/A